3rd ADC Linker and Conjugation Summit

As dual-payload and novel-payload ADCs fuel the next wave of innovation in the ADC space, the spotlight is shifting to the chemistry behind these advancements. With the need for strategies to overcome payload hydrophobicity, achieve optimal stability profiles, and reduce aggregation, linker and conjugation strategies have become crucial levers for unlocking improved therapeutic windows.

Returning to Boston this August, the 3rd ADC Linker and Conjugation Summit is the only meeting fully dedicated to the chemistry that underpins ADC success. Join 80+ experts from AstraZeneca, Pfizer, Sutro Biopharma, Glykos, Catena Biosciences, Tubulis, and more for three days of focused insights and technical exchange.

Uncover innovations in linker design and conjugation chemistry, explore how to conjugate multiple payloads with precision, and discover how structural modifications translate to clinical impact. Whether you're advancing a novel format or striving for greater success with a proven payload, this is your chance to move beyond trial-and-error and build a deeper understanding of the chemistry that matters.

It's time to focus on the key element of the ADC that drives its performance: the linker and conjugation strategy.


URLs:
Website: https://go.evvnt.com/3017744-0?pid=2874
Brochure: https://go.evvnt.com/3017744-3?pid=2874

Category: Conferences | Science, Health & Medicine | Oncology

Prices:
Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4197.00,
Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,
Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 3597.00,
Academic Pricing - (2 Day Pass Conference Only): USD 2599.00,
Service Provider Pricing - (3 Day Pass Conference + Workshop Day): USD 5097.00,
Service Provider Pricing - (2 Day Pass Conference Only): USD 3699.00

Speakers: Lea Rochet, Bioconjugation Scientist, ADC Therapeutics, Philipp Spycher, Chief Scientific Officer and Co-Founder, Araris Bio, Marcello Marelli, Principal Scientist, AstraZeneca, Alice Chen, Chief Scientific Officer, Baylink Biosciences, Marco Lobba, Co-Founder and Chief Executive Officer, Catena Biosciences, Andrea North, Team Leader - Bioconjugates and Biomaterials, CSIRO, Ganapathy Sarma, Director - Antibody Drug Conjugates, Exelixis, Juhani Saarinen, Chief Executive Officer, Glykos, Tero Satomaa, Project Director and Partner, Glykos, Valentin Petrich, Group Leader - Chemistry, Heidelberg Pharma, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Tatiana Novobrantseva, Chief Scientific Officer, NextPoint Therapeutics, Wei Lu, Vice President - Research, OnCusp Therapeutics, Florian Heinkel, Principal Scientist, Antibody Discovery and Engineering, Pfizer, Manel Merabet, Chief Development Officer, Skymab Therapeutics, Krishna Bajjuri, Senior Director - Chemistry, Sutro Biopharma, Marc Robillard, Founder and Chief Scientific Officer, Tagworks, Philipp Ochtrop, Director Chemistry, Tubulis GmbH, Mark Distefano, Professor University of Minnesota